The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high‐risk AML who respond to their initial treatment and are not candidates for allogeneic stem cell transplantation (ASCT) will eventually relapse with poor outcomes.
Methods
In this phase 2 trial, the efficacy of lenalidomide maintenance...
Background
The combination of all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) has proven to be the most effective therapy for patients with acute promyelocytic leukemia (APL). The majority of the morbidity and mortality from APL therapy occur during the induction phase. The objective of the current study was to identify the risk factors associated with transfer to the intensive care unit...
Background
Lymph node (LN) metastases are associated with poor outcomes for patients with renal cell carcinoma (RCC). This study compared the survival outcomes of patients with stage III, node‐positive disease (pT123N1M0) and patients with stage III, node‐negative disease (pT3N0M0).
Methods
A database of 4652 patients with RCC of any histological subtype treated with surgery at The University of...
BACKGROUND
The American Cancer Society (ACS) recommends men have the opportunity to make an informed decision about screening for prostate cancer (PCa). The ACS developed a unique decision aid (ACS‐DA) for this purpose. However, to date, studies evaluating the efficacy of the ACS‐DA are lacking. The authors evaluated the ACS‐DA among a cohort of medically underserved men (MUM).
METHODS
A multiethnic...
BACKGROUND
Predicting outcomes for patients with acute myeloid leukemia (AML) on the basis of pretreatment predictors has been the cornerstone of management. Posttreatment prognostic factors are increasingly being evaluated.
METHODS
Among 280 younger patients who were treated with intermediate‐dose cytarabine (total ≥ 5 g/m2) and idarubicin‐based induction chemotherapy and achieved remission, 186...
BACKGROUNDA high pretreatment β2‐microglobulin (B2M) level is associated with inferior survival outcomes in patients with chronic lymphocytic leukemia. However, to the authors' knowledge, the prognostic and predictive significance of changes in B2M during treatment have not been reported to date.
METHODSThe authors analyzed 83 patients treated with ibrutinib‐based regimens (66 with recurrent/refractory...
BACKGROUND
The treatment of older adults with acute myeloid leukemia (AML) using standard intensive chemotherapy has been associated with poor outcomes. Effective, less toxic therapies are needed to achieve and maintain durable remissions.
METHODS
One hundred eighteen patients with newly diagnosed AML (median age, 68 years; range, 60‐81 years) were treated with a regimen of clofarabine and low‐dose...
BACKGROUNDLittle is known regarding racial disparities in characteristics and outcomes among patients with chronic lymphocytic leukemia (CLL).
METHODSThe characteristics and outcomes of untreated African American (AA) patients with CLL (n = 84) were analyzed and compared with a reference nonblack (NB) patient population (n = 1571).
RESULTSAt the time of presentation, AA patients had lower median...
BACKGROUND:Standard therapy for older patients with acute myeloid leukemia (AML) has a poor outcome. The authors have designed a combination of clofarabine plus low‐dose cytarabine followed by a prolonged consolidation alternating with decitabine.
METHODS:Sixty patients with a median age of 70 years (range, 60‐81 years) with newly diagnosed AML were included. They received clofarabine 20 mg/m2 intravenously...
BACKGROUND:IDH1 and IDH2 gene mutations are novel, recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia (AML).
METHODS:Among 358 patients with AML treated on 4 protocols using high‐dose ara‐C plus idarubicin induction, pretreatment samples were available for 170 (median age 53 years, [range, 17‐73]; 96% ≤65) and were evaluated for IDH1R132, IDH2R172, and IDH2R140...
BACKGROUND:Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified.
METHODS:We retrospectively analyzed the records of 14 patients with histopathologically confirmed HPC/SFT who were treated at...
BACKGROUND:The prognosis of patients with localized gastroesophageal carcinoma (LGC) can be defined after chemoradiation by the standardized uptake value (SUV) of positron emission tomography (PET). High SUV (HSUV) after chemoradiation portends a poor prognosis. The authors retrospectively examined the role of surgery in patients with HSUV after chemoradiation.
METHODS:The authors analyzed the postchemoradiation...
BACKGROUND:Appendiceal neoplasms include tumors ranging from benign‐appearing cells with widespread mucin deposits to aggressive poorly differentiated signet ring cell adenocarcinomas. Traditionally, these tumors are treated with cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy. For some patients, cytoreductive surgery is not an option, and minimal published data exist in...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.